Tidal Investments LLC lifted its holdings in shares of Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY - Free Report) by 492.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 89,248 shares of the company's stock after buying an additional 74,193 shares during the quarter. Tidal Investments LLC owned approximately 0.22% of Brainsway worth $1,384,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. NewEdge Advisors LLC increased its holdings in Brainsway by 434.6% in the 2nd quarter. NewEdge Advisors LLC now owns 18,830 shares of the company's stock worth $292,000 after acquiring an additional 15,308 shares in the last quarter. Ballast Advisors LLC purchased a new stake in Brainsway during the 1st quarter worth approximately $55,000. Bank of America Corp DE acquired a new position in shares of Brainsway during the first quarter valued at approximately $206,000. Royal Bank of Canada raised its holdings in shares of Brainsway by 84.2% during the first quarter. Royal Bank of Canada now owns 15,490 shares of the company's stock valued at $206,000 after acquiring an additional 7,080 shares during the last quarter. Finally, Masters Capital Management LLC lifted its position in shares of Brainsway by 65.0% in the first quarter. Masters Capital Management LLC now owns 1,650,000 shares of the company's stock valued at $21,928,000 after acquiring an additional 650,000 shares in the last quarter. Hedge funds and other institutional investors own 30.11% of the company's stock.
Brainsway Trading Up 0.6%
Shares of BWAY stock opened at $13.61 on Friday. Brainsway Ltd. Sponsored ADR has a twelve month low of $7.14 and a twelve month high of $17.40. The company's 50-day moving average price is $14.91 and its 200-day moving average price is $14.81. The stock has a market cap of $547.26 million, a price-to-earnings ratio of 30.93 and a beta of 1.25.
Brainsway (NASDAQ:BWAY - Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.04. The firm had revenue of $17.11 million during the quarter, compared to analysts' expectations of $16.54 million. Brainsway had a net margin of 15.65% and a return on equity of 12.74%. As a group, equities research analysts predict that Brainsway Ltd. Sponsored ADR will post 0.33 EPS for the current year.
Wall Street Analyst Weigh In
BWAY has been the subject of several research reports. Weiss Ratings downgraded Brainsway from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Wednesday, August 19th. Wall Street Zen raised shares of Brainsway from a "hold" rating to a "buy" rating in a research note on Sunday, August 2nd. Zacks Research lowered shares of Brainsway from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 11th. LADENBURG THALM/SH SH increased their target price on shares of Brainsway from $18.00 to $18.80 and gave the company a "buy" rating in a research report on Thursday, August 13th. Finally, HC Wainwright reissued a "buy" rating and issued a $19.00 price target on shares of Brainsway in a research note on Tuesday, September 8th. Five research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $18.20.
Get Our Latest Report on BWAY
About Brainsway
(
Free Report)
BrainsWay Ltd. is a medical technology company that develops and commercializes noninvasive therapies for brain disorders. Its principal technology, Deep Transcranial Magnetic Stimulation (Deep TMS), uses electromagnetic fields to stimulate targeted areas of the brain and is designed to reach deeper and broader regions than conventional transcranial magnetic stimulation.
The company's product portfolio includes Deep TMS systems, treatment coils, and related software and accessories. Its systems are used by mental health professionals for conditions including major depressive disorder, obsessive-compulsive disorder, and smoking cessation, subject to applicable regulatory clearances and local requirements.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Brainsway, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brainsway wasn't on the list.
While Brainsway currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
